Generics (Gx)
Pharmazac Generics
Pharmazac is a developer of Generic pharmaceutical formulations. With extended R&D capabilities and experience in the global market, we support and expand a portfolio across several therapeutic categories.
Moreover, Pharmazac is a local champion in the Greek pharmaceutical market where more than 70 generic branded generics are now available to Greek patients.
Established Business Units in Primary Care (including Cardiology and Diabetes), Central Nervous System (CNS), Oncology & Urology provide medical information, marketing and market access support for in-house and co-commercialised products, some of them in collaboration with large multinationals. Moreover, a dedicated Hospital line brings into the markets specialized injectable formulations; our Micafungin generic has become a global champion in Greece and in more than 45 countries around the world.
Pharmazac is evolving into a key player in Generics both locally and globally. We emphasize on bringing into the markets high-quality, affordable healthcare solutions.


Generics (Gx)
Our R&D Laboratories
Pharmazac’s R&D laboratories support the development of new pharmaceutical products and the continuous improvement of existing formulations. Our scientific teams work across formulation development, analytical method development, stability studies and technical evaluation of new product opportunities.
Our laboratories play a central role in transforming ideas into viable development projects, ensuring that each product is assessed with scientific, regulatory and commercial criteria.
As of 2025 Pharmazac maintains R&D Operations across its sites in Athens, Lamia and predominantly Keratea, where a 1.200 sq.m. manufacturing and analytical development suite has been established. Our laboratories are GMP certified and apply state-of-the-art SOPs implemented by our highly educated and trained human capital.
Generics (Gx)
Our R&D Projects
Our development projects reflect Pharmazac’s commitment to building a future-oriented pharmaceutical portfolio. We evaluate and develop products based on therapeutic value, market potential, technical feasibility and regulatory requirements.
Each project is managed with a clear focus on quality, timelines and long-term business relevance. Through this disciplined approach, Pharmazac continues to strengthen its pipeline and expand its capabilities in selected therapeutic areas.
Our R&D pipeline is focused on dry forms formulations in diabetes, CNS, cardiology and blood diseases but is now expanding to more than 10 therapeutic categories. Visit our International Portfolio of products for more information on our R&D plans.

PHARMAZAC
Recent Launches
